Evidence map›Paper›PMID 37589076›Full record

ArticleEMBO molecular medicine2023

Functional analysis reveals driver cooperativity and novel mechanisms in endometrial carcinogenesis.

Matthew Brown, Alicia Leon, Katarzyna Kedzierska, Charlotte Moore, Hayley L Belnoue-Davis, Susanne Flach, John P Lydon, Francesco J DeMayo, Annabelle Lewis, Tjalling Bosse and 2 more

Open access · goldAbstract read
In one paragraph

Article in EMBO molecular medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.8field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors at 7 institutions in 4 countries.

Matthew BrownCancer Genomics and Immunology Group, Wellcome Centre for Human Genetics, University of Oxford, Oxford, UK.ORCID 0000-0002-0299-514X
Alicia LeonDepartment of Pathology, Leiden University Medical Center, Leiden, The Netherlands.
Katarzyna KedzierskaCancer Genomics and Immunology Group, Wellcome Centre for Human Genetics, University of Oxford, Oxford, UK.
Charlotte MooreCancer Genomics and Immunology Group, Wellcome Centre for Human Genetics, University of Oxford, Oxford, UK.ORCID 0000-0002-7932-1442
Hayley L Belnoue-DavisGastrointestinal Stem Cell Biology Laboratory, Wellcome Centre for Human Genetics, University of Oxford, Oxford, UK.ORCID 0000-0003-2914-4932
Susanne FlachDepartment of Otorhinolaryngology, Head and Neck Surgery, LMU Klinikum, Munich, Germany.
John P LydonDepartment of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX, USA.
Francesco J DeMayoReproductive and Developmental Biology Laboratory, National Institute of Environmental Health Sciences, Research Triangle Park, NC, USA.
Annabelle LewisDepartment of Life Sciences, College of Health, Medicine and Life Sciences, Brunel University London, Uxbridge, UK.
Tjalling BosseDepartment of Pathology, Leiden University Medical Center, Leiden, The Netherlands.
Ian TomlinsonInstitute of Genetics and Cancer, The University of Edinburgh, Edinburgh, UK.
David N ChurchCancer Genomics and Immunology Group, Wellcome Centre for Human Genetics, University of Oxford, Oxford, UK.ORCID 0000-0002-4617-962X
Centre for Human Genetics · GBLeiden University Medical Center · NLBaylor College of Medicine · USBrunel University of London · GBEdinburgh Cancer Research · GBGerman Cancer Research Center · DENational Institute of Environmental Health Sciences · US

Funding

Environmental Signaling in Reproduction and PregnancyZIAES103311 · NIEHS · NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES · PI DEMAYO, FRANCESCO · 2016 to 2025
$30.5M
Molecular Analysis of Uterine ReceptivityR01HD042311 · NICHD · BAYLOR COLLEGE OF MEDICINE · PI LYDON, JOHN P · 2009 to 2023
$4.8M
Cancer Research UK 27963Intramural NIH HHS ZIA ES103311Medical Research Council MR/P000738/1Medical Research Council MR/P000738/2Medical Research Council MR/R014124/1NICHD NIH HHS R01 HD042311Wellcome Trust
6 · The paper itself

Abstract

High-risk endometrial cancer has poor prognosis and is increasing in incidence. However, understanding of the molecular mechanisms which drive this disease is limited. We used genetically engineered mouse models (GEMM) to determine the functional consequences of missense and loss of function mutations in Fbxw7, Pten and Tp53, which collectively occur in nearly 90% of high-risk endometrial cancers. We show that Trp53 deletion and missense mutation cause different phenotypes, with the latter a substantially stronger driver of endometrial carcinogenesis. We also show that Fbxw7 missense mutation does not cause endometrial neoplasia on its own, but potently accelerates carcinogenesis caused by Pten loss or Trp53 missense mutation. By transcriptomic analysis, we identify LEF1 signalling as upregulated in Fbxw7/FBXW7-mutant mouse and human endometrial cancers, and in human isogenic cell lines carrying FBXW7 mutation, and validate LEF1 and the additional Wnt pathway effector TCF7L2 as novel FBXW7 substrates. Our study provides new insights into the biology of high-risk endometrial cancer and suggests that targeting LEF1 may be worthy of investigation in this treatment-resistant cancer subgroup.

Indexed as

CarcinogenesisEndometrial NeoplasmsAnimalsF-Box-WD Repeat-Containing Protein 7FemaleHumansMiceMutationMutation, MissenseF-Box-WD Repeat-Containing Protein 7Driver genesEndometrial cancerFbxw7Functional modelsGEMM

Identifiers

PMID37589076
PMCPMC10565641
OpenAlexW4385897967

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.